Anti tim 3 f38 2e2

Manufactured by BioLegend

Sourced in United States

Anti-Tim-3 (F38-2E2) is a monoclonal antibody that binds to the T-cell immunoglobulin and mucin domain-containing protein 3 (Tim-3). Tim-3 is an inhibitory receptor expressed on various immune cells, including T cells, natural killer cells, and myeloid cells. The Anti-Tim-3 (F38-2E2) antibody can be used for the detection and study of Tim-3 expression and function.

Automatically generated - may contain errors

Lab products found in correlation

Anti lag 3 11c3c65, by BioLegend (3 mentions) Anti pd 1 eh12, by BD (3 mentions) Permeabilization buffer, by Thermo Fisher Scientific (2 mentions) Anti tigit mbsa43, by Thermo Fisher Scientific (2 mentions) Anti ifn γ 4s b3, by Thermo Fisher Scientific (2 mentions) Il 10 jes3 9d7, by BioLegend (2 mentions) Cytofix fixation buffer, by BD (2 mentions) Live dead fixable near ir dead cell stain kit, by Thermo Fisher Scientific (2 mentions) Ionomycin, by Merck Group (2 mentions) Phorbol 12 myristate 13 acetate, by Merck Group (2 mentions) Brefeldin a, by BD (2 mentions) Celltrace violet, by Thermo Fisher Scientific (2 mentions) Propidium iodide, by Thermo Fisher Scientific (1 mentions) Precision count beads, by BioLegend (1 mentions) Zombie yellow viability dye, by BioLegend (1 mentions) Ghost red 780, by Cytek Biosciences (1 mentions) Anti cd3 ucht1, by BioLegend (1 mentions) Anti cd69 fn50, by BioLegend (1 mentions) Anti cd25 bc96, by BioLegend (1 mentions) Anti mouse cd45 30 f11, by BioLegend (1 mentions)

Close spelling variants of this product

Anti-Tim-3 mAb (clone F38-2E2, Tim-3 (F38-2E2) Anti-TIM-3 TIM-3

5 protocols using anti tim 3 f38 2e2

Comprehensive Immunological Antibody Panel

Check if the same lab product or an alternative is used in the 5 most similar protocols

The following antibodies were used in this study: anti-B7-H3 (FM276, Miltenyi Biotech), anti-GD2 (14.G2a, BD Biosciences), human Ig (polyclonal, Thermo Fisher Scientific), anti-mouse IgG (polyclonal, R&D), anti-CD3 (UCHT1, BioLegend), anti-HisTag (J095G45, BioLegend), anti-CD34 (QBEnd10, R&D), anti-ab-TCR (IP26, BioLegend), anti-CD107a (H4A3, BioLegend), anti-cD25 (BC96, BioLegend), anti-CD69 (FN50, BioLegend), anti-Tim3 (F38-2E2, BioLegend), anti-Lag3 (11C3C65, BioLegend), anti-PD-1 (EH12.1, BD Biosciences), anti-mouse CD45 (30-F11, BioLegend), anti-human CD45 (HI30, BioLegend), Ghost Red 780 (Tonbo Biosciences), Zombie Yellow Viability Dye (BioLegend), propidium iodide (Gibco), Cell Trace Violet (Thermo Fisher Scientific), and Precision Count Beads (BioLegend).

Birley K., Leboreiro-Babe C., Rota E.M., Buschhaus M., Gavriil A., Vitali A., Alonso-Ferrero M., Hopwood L., Parienti L., Ferry G., Flutter B., Himoudi N., Chester K, & Anderson J. (2022). A novel anti-B7-H3 chimeric antigen receptor from a single-chain antibody library for immunotherapy of solid cancers. Molecular Therapy Oncolytics, 26, 429-443.

+ Open protocol

+ Expand

Multiparameter Immune Profiling of Cells

Check if the same lab product or an alternative is used in the 5 most similar protocols

Cells were stained with LIVE/DEAD Fixable Near-IR Dead Cell Stain kit (Invitrogen) and surface antibodies for 30 min at 4 °C. For intracellular cytokine staining, cells were treated with 50 nM phorbol-12-myristate-13-acetate (MilliporeSigma) and 250 nM ionomycin (MilliporeSigma) for 4 hours in the presence of Brefeldin A (BD Biosciences) before harvesting. Cells were washed and fixed with BD Cytofix™ Fixation Buffer (BD Biosciences) for 10 min at RT, then washed with PBS. Intracellular cytokines were stained in permeabilization buffer (eBioscience) for 30 min at 4 °C. The following antibodies were used: anti-LAG-3 (11C3C65, BioLegend), anti-PD-1 (EH12.1, BD Biosciences), anti-TIGIT (MBSA43, eBioscience), anti-Tim-3 (F38–2E2, Biolegend), anti-IFN-γ (4S.B3, eBioscience), and IL-10 (JES3–9D7, Biolegend). Cells were acquired on a BD Fortessa flow cytometer and data was analyzed with FlowJo software v10 (Threestar).

Sumida T.S., Dulberg S., Schupp J., Stillwell H.A., Axisa P.P., Comi M., Lincoln M., Unterman A., Kaminski N., Madi A., Kuchroo V.K, & Hafler D.A. (2020). Type I Interferon Transcriptional Network Regulates Expression of Coinhibitory Receptors in Human T cells. bioRxiv.

+ Open protocol

+ Expand

Phenotypic Profiling of Immune Cells

Check if the same lab product or an alternative is used in the 5 most similar protocols

Cells were stained with LIVE/DEAD Fixable Near-IR Dead Cell Stain kit (Invitrogen) and surface antibodies for 30 min at 4 °C. For intracellular cytokine staining, cells were treated with 50 nM phorbol-12-myristate-13-acetate (MilliporeSigma) and 250 nM ionomycin (MilliporeSigma) for 4 hours in the presence of Brefeldin A (BD Biosciences) before harvesting. Cells were washed and fixed with BD Cytofix™ Fixation Buffer (BD Biosciences) for 10 min at RT, then washed with PBS. Intracellular cytokines were stained in permeabilization buffer (eBioscience) for 30 min at 4 °C. The following antibodies were used: anti-LAG-3 (11C3C65, BioLegend), anti-PD-1 (EH12.1, BD Biosciences), anti-TIGIT (MBSA43, eBioscience), anti-Tim-3 (F38-2E2, Biolegend), anti-IFN-γ (4S.B3, eBioscience), and IL-10 (JES3-9D7, Biolegend). Cells were acquired on a BD Fortessa flow cytometer and data was analyzed with FlowJo software v10 (Threestar).

Hafler D., Sumida T., Dulberg S., Schupp J., Stillwell H., Axisa P.P., Comi M., Lincoln M., Unterman A., Kaminski N., Madi A, & Kuchroo V. (2021). Type I Interferon Transcriptional Network Regulates Expression of Coinhibitory Receptors in Human T cells. Research Square.

+ Open protocol

+ Expand

Blocking Immune Checkpoint Receptors

Check if the same lab product or an alternative is used in the 5 most similar protocols

Cells were pre-coated with 10µg/ml blocking antibodies before co-culture. Antibodies used were anti-PD-L1 (6E11.1.9, Genentech), anti-PD-1 (EH12.2H7, BioLegend), anti-Tim-3 (F38-2E2, BioLegend), mouse IgG2a isotype (BioLegend), and mouse IgG1 isotype (BioLegend).

Lee Y., Shin J.H., Longmire M., Wang H., Kohrt H.E., Chang H.Y, & Sunwoo J.B. (2016). CD44+ cells in head and neck squamous cell carcinoma suppress T cell-mediated immunity by selective constitutive and inducible expression of PD-L1. Clinical cancer research : an official journal of the American Association for Cancer Research, 22(14), 3571-3581.

+ Open protocol

+ Expand

NK Cell Purification and Functional Assay

Check if the same lab product or an alternative is used in the 5 most similar protocols

For separation of NK cells, anti-CD56 microbeads, columns, and filters were purchased from Miltenyi Biotec (Bergisch Gladbach, Germany). For purity analysis of NK cells, anti-CD56 monoclonal antibody (TULY 56)-FITC and anti-CD3 monoclonal antibody (UCHT1)-PE together with their relevant mouse IgG1-kappa isotype controls were purchased from eBioscience (California, United States). For stimulation of NK cells, human interleukin-2 (IL-2) recombinant protein and cell stimulation cocktail (×500) were purchased from eBioscience (California, United States). Blocking antibodies, anti-PD-1 (EH12-27) and anti-Tim-3 (F38-2E2) and their corresponding purified IgG1-kappa isotype controls were from BioLegend (California, United States). Anti-CD107a (LAMP-1) monoclonal antibody (eBioH4A3)-PE and Annexin V-FITC Apoptosis Detection Kit with PI were purchased from eBioscience (California, United States). For cytokines measurements, human IFN-γ and TNF-α ELISA kits were obtained from eBioscience (California, United States).

Astaneh M., Rezazadeh H., Hossein-Nataj H., Shekarriz R., Zaboli E., Shabani M, & Asgarian-Omran H. (2022). Tim-3 and PD-1 blocking cannot restore the functional properties of natural killer cells in early clinical stages of chronic lymphocytic leukemia: An in vitro study. Journal of cancer research and therapeutics, 18(3).

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!